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 Th e study of the mechanisms of transcrip-
tion and translation of heme oxygenase-1 
(HO-1) and its multiple functions using 
 in vitro and  in vivo animal models has 
demonstrated that the benefi cial cytopro-
tective eff ects of HO-1 are due not only to 
its function in heme degradation and iron 
reutilization, but also to the potent anti-
infl ammatory, antioxidant, antiapoptotic, 
and vasorelaxant properties of its reaction 
products. Furthermore, in the clinical set-
ting, a number of studies have shown the 
cytoprotective role of HO-1 in various 
disease states, such as renal ischemia /
 reperfusion, glomerulonephritis, rhabdo-
myolysis, nephrotoxins, and renal 
transplant rejection. Functional studies 
imply the use of pharmacological maneu-
vers that have effects beyond altering 
HO-1 activity per se. Side eff ects of met-
allophorphyrin inhi bitors of HO aff ect 
other enzymes such as nitric oxide syn-
thase and guanylate cyclase, in addition 
to other nonspecifi c eff ects. Th us, the full 
importance of HO-1 in physiological and 
pathological states cannot be shown by 
functional studies. 
 To circumvent this difficulty, a HO-1 
knockout mouse ( Hmox1   −  /  −   ) was deve-
loped. Poss and Tonegawa 1 observed that 
kidneys of  Hmox1   −  /  −   mice showed evi-
dence of iron deposition in renal cortical 
tubules accompanied by a progressive 
chronic inflammation characterized by 
hepatosplenomegaly, lymphadenopathy, 
leukocytosis, hepatic periportal infl amma-
tion, iron deposition, and occasionally 
glomerulonephritis. The animals were 
more sensitive to oxidant stimuli. 1 In 
another study, 2 these authors also found 
that  Hmox1  /  embryonic fi broblasts demon-
strated high oxygen free radical production 
when exposed to hemin, hydrogen perox-
ide, paraquat, or cadmium chloride, and 
they were hypersensitive to cytotoxicity 
caused by hemin and hydrogen peroxide. 
Furthermore, young adult  Hmox1  − / −  mice 
were vulnerable to mortality and hepatic 
necrosis when challenged with endotoxin. 2 
On the other hand, the fi rst known human 
case of defi ciency in HO-1 production was 
reported. 3 The patient was a 6-year-old 
boy who presented with severe growth 
retardation and persistent hemolytic ane-
mia characterized by marked erythrocyte 
fragmentation and intravascular hemolysis, 
with a paradoxical increase of serum hap-
toglobin and low bilirubin. An abnormal 
coagulation / fi brinolysis system, associated 
with elevated thrombomodulin and von 
Willebrand factor, indicated the presence 
of severe, persistent endothelial damage. 
Continuous hematuria and proteinuria 
were accompanied by histological fi ndings 
that revealed detachment of endothelium, 
with subendothelial deposition of an uni-
dentifi ed material in the glomeruli with 
iron deposition in renal and hepatic tissues. 
The patient was extremely sensitive to 
hemin-induced cell injury and died before 
reaching adulthood. 
 In a more advanced step in research, 
cytoprotective eff ects of HO-1 have been 
studied with the use of transgenic mouse 
models bearing human HO-1 under control 
of diff erent human promoters, thus present-
ing organ-specific human HO-1 over-
expression. Minamino  et al. 4 reported 
that targeted expression of human HO-1 
prevents the pulmonary infl ammatory and 
vascular responses to hypoxia. Yet  et al. 5 
observed that cardiac-specifi c expression 
of human HO-1 protects against ischemia 
and reperfusion injury in transgenic mice, 
and Duann and Lianos, 6 using a mouse 
model of immune injury directed against 
renal glomerular vasculature resembling 
human forms of glomerulonephritis, 
observed that injury by administration of 
antibody against the glomerular basement 
membrane was attenuated in the human 
transgenic mice as compared with wild-type 
controls. 
 Although the main function of HO-1, 
heme degradation and cytoprotection, is 
the same in both humans and rodents, it is 
diffi  cult to extrapolate the analysis of the 
human HO-1 gene obtained in animal 
studies to what may be occurring in phys-
iological conditions in the human body, 
because of major diff erences in the molec-
ular regulation of mouse and human 
genes. 7,8 For example, the mouse HO-1 
gene possesses two distal promoter regions, 
E1 and E2, that contain the stress response 
elements that seem to mediate, exclusively, 
the response to a variety of stimuli, such 
as heme, nitric oxide, heavy metals (cad-
mium), hydrogen peroxide, hyperoxia, 
lipopolysaccharide, phorbol ester, sodium 
arsenite, and various electrophiles. How-
ever, the analogous regions of the human 
gene (regions A and B) are only partially 
responsive to heme and cadmium and are 
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not responsive to hyperoxia, hydrogen 
peroxide, or oxidized lipids. Moreover, 
hypoxia, heat shock, or cytokines such as 
interferon- γ induce HO-1 in mouse but 
repress it in human cells. Also, an internal 
enhancer in the human HO-1 gene is not 
present in rodent cells. Furthermore, mul-
tiple regulatory regions within the HO-1 
gene interact with each other via chroma-
tin looping, and a transcription factor, 
specificity protein 1 (Sp1), mediates 
changes in chromatin conformation and 
initiation of human HO-1 transcription in 
renal epithelial cells  in vitro (see Sikorski 
 et al. 7 and Ryter and Choi 8 for a more 
detailed analysis). 
 Transfection methodology between spe-
cies can be considered as a very potent tool 
for studying the role of HO-1 against tissue 
injury beyond the limitations of separate 
animal and human studies. In the trans-
genic animals generated so far, the trans-
fected human HO-1 gene has generally 
been linked to a specifi c promoter, so that 
the human HO-1 gene has been expressed 
in specifi c organs (skin, heart, kidney, or 
lung) and only the human gene is respon-
sive to a particular stimulus. In addition, in 
these models mouse and human HO-1 
genes have coexisted. Kim  et al. 9 (this 
issue) now report a novel  in vivo model for 
studying the functional and regulatory 
mechanisms of the human HO-1 gene via 
the generation of  ‘ humanized ’ HO-1 BAC 
transgenic mice. Th e authors generated 
transgenic mice harboring a 7-kb bacterial 
artifi cial chromosome (BAC) that express 
human HO-1 mRNA and protein. Th ese 
mice were bred with  HO-1   −  /  −   mice to gen-
erate humanized BAC transgenic mice. Th e 
transgenic hHO-1 BAC mouse has the 
endogenous HO-1 gene knockout and 
contains the complete human HO-1 gene 
with all its regulatory elements. Th e authors 
found that the human HO-1 gene product 
in hHO-1 BAC mice successfully rescued 
the phenotype of the  HO-1   −  /  −   mice, 
including reduced birth rates, tissue iron 
overload, splenomegaly, anemia, leukocy-
tosis, dendritic-cell abnormalities, and 
survival aft er acute kidney injury induced 
by rhabdomyolysis and cisplatin nephro-
toxicity. Th ey also found that transcription 
factors such as USF1 / 2, JunB, Sp1, and 
CTCF associate with regulatory regions of 
the human HO-1 gene in the kidney fol-
lowing rhabdo myolysis, and 3C and ChIP-
loop assay confi rmed their involvement in 
the formation of chromatin looping  in vivo . 
Th ey also identifi ed the involvement of 
CTCF, a master regulator of HO-1 gene 
expression  in vivo and  in vitro . Th e study 
also shows that although humanized BAC 
mice overexpress HO-1 in basal, non-stim-
ulated conditions, there is still capacity for 
signifi cant inducibility of the human HO-1 
gene. Th us, this model of humanized HO-
1 BAC mice 9 will serve as a valuable model 
system to study the  in vivo architecture 
of the human HO-1 gene and will clarify 
the  in vivo regu lation of the HO-1 gene 
in acute kidney injury as well as other 
diseases. 
 Th is transgenic mouse model has, how-
ever, some limitations. To study human 
HO-1 gene regulation under basal, 
non-stimulated conditions requires 
an adequate capacity of response to any 
stimulus able to induce HO-1 expression, 
and a mechanism able to maintain a 
response that is adequate to the stimulus 
both in intensity and in length of time. In 
the work of Kim  et al. , 9 HO-1 is overex-
pressed; the response to glycerol is slow 
to develop, the decrease back to normal 
is too fast, and at any time the protein lev-
els are too high as compared with those 
in  HO-1   +  /  +   mice. This also raises the 
question of whether less damaging dis-
ease model that confers subtle damage 
over longer periods of time may be 
obscured simply by the higher back-
ground expression of HO-1 in these ani-
mals so that the response to some of the 
stimuli that up- or downregulate HO-1 
may not be observed. Th e other face of 
the coin is that over expression of HO-1 
may be detrimental — instead of protec-
tive (hormetically) — to the normal phys-
iology of human HO-1 BAC mice, as may 
be suggested by the presence of Howell –
 Jolly bodies in the red blood cells of these 
animals. 
 The animal model presented by Kim 
 et al. 9 is not fully characterized. There 
are a number of questions to be answered. 
For instance, may the expression of 
this human HO-1 enzyme be inhibited? Is 
there any change in serum levels of 
bilirubin? Is the cellular redox state altered 
by HO-1 overexpression? Another ques-
tion of interest is whether the trans cription 
factors Nrf2 and Bach1 , important regula-
tors of the mouse HO-1 gene , are involved 
in regulation of the human HO-1 gene. 
 DISCLOSURE 
 The authors declared no competing interests. 
 ACKNOWLEDGMENTS 
 The authors acknowledge funding from 
Fundaci ó n S é neca (grant 12009 / PI / 09). 
 REFERENCES 
 1 .  Poss  KD ,  Tonegawa  S .  Heme oxygenase 1 is 
required for mammalian iron reutilization . 
 Proc Natl Acad Sci USA  1997 ;  94 :  10919 – 10924 . 
 2 .  Poss  KD ,  Tonegawa  S .  Reduced stress defense in 
heme oxygenase 1-deficient cells .  Proc Natl Acad 
Sci USA  1997 ;  94 :  10925 – 10930 . 
 3 .  Yachie  A ,  Niida  Y ,  Wada  T  et al.  Oxidative stress 
causes enhanced endothelial cell injury in human 
heme oxygenase-1 deficiency .  J Clin Invest  1999 ; 
 103 :  129 – 135 . 
 4 .  Minamino  T ,  Christou  H ,  Hsieh  CM  et al.  Targeted 
expression of heme oxygenase-1 prevents the 
pulmonary inflammatory and vascular responses 
Features
• Complete absence of mouse HO-1
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regulatory elements
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• To study the physiological regulation 
  of human HO-1 under basal, 
  non-stimulated conditions is not possible 
• Pharmacological studies using low
  intensity stimuli are difficult or not possible 
hHO-1 BAC
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 Podocyte ACE2 protects against 
diabetic nephropathy 
 Raymond C.  Harris 1 
 As new components of the renin – angiotensin system (RAS) are 
elucidated, our understanding of the complexities of their interactions 
also advances. Previous studies have determined that podocytes 
possess a local RAS that can generate angiotensin II. Podocytes have 
also been shown to express angiotensin-converting enzyme 2 (ACE2), 
which can decrease angiotensin II levels by generation of angiotensin-
(1 – 7). Nadarajah  et al. now show that increased podocyte ACE2 activity 
can attenuate the development of diabetic nephropathy. 
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 Th e renin – angiotensin system (RAS) is 
phylogenetically ancient, and its impor-
tance in the maintenance of physiologic 
homeostasis is reflected by the tens of 
thousands of publications on the subject. 
However, although renin was fi rst des-
cribed in 1898 and angiotensin in 1936, 
investigators continue to discover new 
facets of the RAS. Th e role of the mono-
carboxyl peptidase angiotensin-convert-
ing enzyme 2 (ACE2) in physiology and 
pathophysiology has attracted increasing 
interest. While ACE converts the decapep-
tide angiotensin I to angiotensin II by 
removing the two distal amino acids, 
ACE2 can act on both angiotensin I and 
angiotensin II. In both situations, it 
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removes the most distal amino acid, lead-
ing to production of angiotensin-(1 – 9) 
(Ang-1 – 9) and angiotensin-(1 – 7) (Ang-
1 – 7), respectively. Ang-1 – 9 is then further 
metabolized by ACE to give Ang-1 – 7. 
Although ACE2 shares approxi mately 
40 % homology with the classic ACE, it 
is the product of a separate gene and 
is under separate regulatory control. 1 
Importantly, ACE inhibitors in clinical 
practice do not inhibit ACE2. 
 In general, studies have indicated that 
ACE2-mediated responses counteract 
those generated by ACE-mediated pro-
duction of angiotensin II and promote 
vasodilation, natriuresis, and cytoprotec-
tion. Mice with global ACE2 deletion have 
increased responsiveness to RAS activa-
tion. 2 Maternal ACE2 defi ciency leads to 
fetal growth restriction, possibly second-
ary to increased placental concentrations 
of angiotensin II. 3 ACE2 has also been 
implicated in regulation of oxidative stress 
in the paraventricular nucleus and rostral 
ventrolateral medulla, which may modu-
late sympathetic tone and blood pressure. 
Although in a manner that is not related 
to its role in regulation of the RAS, ACE2 
serves as the receptor in the lung for the 
severe acute respiratory syndrome coro-
navirus, and ACE2-defi cient mice do not 
develop lung injury upon exposure to the 
virus. 4 
 Th ere remains uncertainty about exactly 
how ACE2 ’ s eff ects are mediated. On the 
one hand, by conversion of both angio-
tensin I and angiotensin II to Ang-1 – 7, 
ACE2 modulates the amount of angio tensin 
II that is available to activate angio tensin II 
type 1 receptors, while on the other 
hand, Ang-1 – 7 is itself a ligand for the Mas 
receptor, activation of which has been 
reported to mediate vaso dilation, natriure-
sis, and reductions in blood pressure. 5 
Depending on the tissue and the patho-
physiologic condition, one or the other of 
these mechanisms may predominate, or 
they may work in concert. In any event, 
abnormalities in ACE2 expression and / or 
activity have now been implicated in a 
range of disorders, including hypertension, 
cardiovascular disease, and diabetic nephro-
pathy. 
 Studies in patients with diabetic 
nephropathy have shown increases in the 
ACE / ACE2 ratio in both glomerulus and 
tubulo interstitium, due largely to decreased 
ACE2 expression. 6 Previous studies in dia-
betic mice found that either global ACE2 
deletion or pharmacologic ACE2 inhibi-
tion exacerbated development of diabetic 
nephropathy. 7,8 Although these studies did 
not report any alterations of blood pressure 
with inhibition of ACE2 activity or expres-
sion, amelioration of diabetic nephropathy 
with systemic administration of recom-
binant ACE2 or increases in systemic 
ACE2 by adenoviral expression was associ-
ated with decreases in blood pressure, 9,10 
making it difficult to discern whether 
beneficial effects of ACE2 were a local 
response in the kidney or were secondary 
to systemic eff ects on blood pressure. 
 In the glomerulus, the podocyte 
expresses many components of the RAS, 
including the (pro)renin receptor, angio-
tensinogen, ACE, and the angiotensin II 
type 1 receptor. 11 Podocytes also express 
ACE2, 12 although glomerular expression 
of the Mas receptor remains uncertain. In 
previous studies, Mas was detected not in 
